Bullish & Foolish
Full SNGX fundamentals All 466 on the Survival Watch

SNGXSOLIGENIX, INC.

Is Soligenix struggling financially?

Yes, by its own account. Soligenix told the SEC on 8 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$8.7M
Source filing
10-Q 8 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 9months

    If the burn speeds up

    Empty by Mar 2027

  • 14months

    If it eases off

    Empty by Aug 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$9.8M

÷

Cash burned over the last 12 months

$10.3M

What Soligenix told the SEC

…as of the date of this filing, the Company does not have sufficient cash and cash equivalents to fund operations for at least 12 months. These factors raise substantial doubt about the Company’s ability to continue as a going concern. To mitigate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, the Company’s plans include securing: additional capital,…

SOLIGENIX, INC., Form 10-Q, filed 8 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 315.4% share-count increase The company issued stock. Each share now owns 75.9% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 31% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt